| Literature DB >> 23418512 |
Jinpu Yu1, Xiubao Ren, Yongzi Chen, Pengpeng Liu, Xiyin Wei, Hui Li, Guoguang Ying, Kexin Chen, Hans Winkler, Xishan Hao.
Abstract
AIM: To investigate the role of neurotensin (NTS) in hepatocellular carcinoma (HCC) sub- grouping and the clinical and pathological significance of activation of NTS/IL-8 pathway in HCC.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23418512 PMCID: PMC3572009 DOI: 10.1371/journal.pone.0056069
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Quality control test of microarray was conducted for 20 cases of HCC samples and according normal adjacent tissues using the SimpleAffy package of Bioconductor 2.4. A-C).
The QC results demonstrated that all RNA samples are in good quality without degradation, the signal intensities of each samples on chips are comparably distributed, and the hybridization signals of specific control genes are overlapped among chips. (A) Degree of RNA degradation. (B) Signal intensity of primary data. (C) Signal intensity of control genes.
Figure 2A subgroup of NTS high expressing HCC is identified from the gene expression profiling data of 10 pairs of in-house HCC tissues and corresponding adjacent normal tissues.
Different subgroups of HCC samples were separated by the unsupervised filtering analysis SMA algorithm. In SMA, the sample names were shown in colorful squares. The genes were depicted in black circles and the size of the circle reflected the mean expression level of the gene over all samples. The subgroups of samples were separated using rectangles in different color, and the characteristic gene signature of certain subgroup was included in the corresponding rectangle as well. A). In Figure 2A, 3 subgroups of 20 cases of samples with distinct expression profiling features are separated along the X(PC1) axis and Y(PC2) axis. PC1 contributes 47% of variability and PC2 contributed 18% of variability in the gene expression profiling data of all 20 samples. The most significantly differentially expressed genes in each subgroup were listed in the same direction and included in the corresponding rectangle as well. Two HCC samples (c-13426 and c-13732, red rectangle) were distinguished from the others 8 cases of HCC samples (blue rectangle) and 10 cases of corresponding adjacent normal tissues (green rectangle) in the spectral map. NTS (red arrow), KRT19 and MMP12 were screened out as highly expressed genes in these 2 samples. B). The SMA was repeated in 10 cases of HCC samples which were divided into 2 subgroups scattering around the central marker “+”. Two HCC samples (c-13426 and c-13732, red rectangle) were separated out of the others 8 cases of HCC samples (blue rectangle), in which the NTS gene showed relatively higher expression in these 2 samples (red arrow). C). Quantity of NTS expression at mRNA level in the HCC tissues and adjacent normal tissues. The green plots represent cancer tissue samples, and the red plots represent normal adjacent tissue samples.
Figure 3Genes differentially expressed between NTS high and low expressing HCC tissues were screened out.
A total of 1274 genes differentially expressed between the NTS high and low expressing HCC samples were identified using LIMMA analysis, in which 579 genes were up-regulated and 695 genes were down-regulated. Hyper-geometric pathway enrichment analysis showed that the down-regulated genes are mainly involved in coagulation and metabolism, whereas the up-regulated genes contribute to inflammation-related biological progresses and HIF-1α and/or Wnt/β-catenin mediated EMT processes.
Pathways enriched from differentially expressed genes between HCC tissues of high and low NTS expression by PathwayStudio™.
| Pathways enriched by Pathway Studio® | Number of overlapping genes | Overlapping genes | P value |
|
| |||
| Lipid metabolic process | 48 | CYP7A1,ACOX2,EHHADH,INSIG1,LRP5,HSD17B6,PLTP,HPGD,ACOT12,CYP3A4,PON1,TTPA,ACSL5,HSD11B1,ACAA2,ACSL6,LPA,SLC27A5,PLA1A,HADH,APOC4,BAAT,RDH16,APOE,ACSM5,ALDH3A2,ACSM3,HSD17B10,SLC27A3,SULT2A1,ABCB4,THRSP,SRD5A2,DGAT2,PLCL2,ACSL1,AKR1D1,ECH1,PMVK,ACADSB,AADAC,ACADL,FADS1,APOB,ACSM1,ECHDC2,CYP7B1,MBTPS2 | 3.184e−22 |
| Fatty acid metabolic process | 27 | ACSM5,FABP4,ACOX2,PCCA,EHHADH,GPAM,ACSM3,SC4MOL,CYP4A11,HPGD,ACOT12,SLC27A3,CYB5A,CRYL1,ACSL5,HAO2,ACSL1,ACAA2,ACSL6,ECH1,SLC27A5,ACADSB,ACADL,HADH,BAAT,ACSM1,ECHDC2 | 1.623e−20 |
| Steroid metabolic process | 14 | CYP7A1,INSIG1,HSD17B6,AKR1B10,SULT2A1,OSBPL6,HSD11B1,CYP3A5,AKR1D1,NR1I2,OSBPL3,APOB,CYP7B1,MBTPS2 | 1.932e−8 |
| Aldehyde metabolic process | 6 | ALDH3A2,AKR7A3,AKR1B10,ALDH7A1,ADH4,ALDH1A1 | 1.547e−7 |
| Blood coagulation | 13 | SERPINC1,F9,F5,F7,LMAN1,SERPIND1,F11,PLG,LPA,COCH,SERPINE1,F13B,F10 | 2.841e−7 |
| Amino acid metabolic process | 10 | SLC7A5,SDS,CLN3,GLUD1,TAT,HMGCL,MAT1A,SLC7A2,OTC,ASNS | 1.296e−6 |
| Cholesterol metabolic process | 10 | CYP7A1,INSIG1,CYP27A1,PON1,TNFSF4,NR0B2,APOB,CYP7B1,APOE,MBTPS2 | 1.535e−5 |
| Biotin metabolic process | 3 | PCCA,MCCC1,BTD | 1.954e−5 |
| Bile acid metabolic process | 5 | ACOX2,AMACR,SLC27A5,AKR1C1,BAAT | 4.794e−5 |
| Acyl-CoA metabolic process | 6 | EHHADH,ACOT12,SLC27A3,GLYAT,HMGCL,ACSL6 | 5.458e−5 |
|
| |||
| Inflammatory response | 21 | CXCL2,CCL16,CCL5,KNG1,CCR5,TNFSF4,NFKBIZ,ATRN,IL8,BLNK,CCL25,CCL8,SPP1,CDO1,EPHX2,EVI1,AOX1,ALOX5AP,CYP4F11,CRP,CYP4F2 | 1.848e−4 |
| Response to reactive oxygen species | 4 | CAT,ALDH3A2,SERPINE1,APOE | 7.370 e−4 |
| Acute-phase response | 6 | CEBPA,LBP,ASS1,HPR,CRP,BAAT | 7.567e−4 |
| Complement activation | 7 | MASP2,C4BPA,C8B,CRP,MBL2,C7,C6 | 9.159e−4 |
| Chemotaxis | 11 | CXCL2,CCL15,CCL16,CCL5,SERPIND1,CCR5,C5AR1,IL8,CCL25,LECT2,CCL8 | 0.002178 |
| Immune response | 34 | CXCL2,MASP2,COLEC12,CCL14,CCL16,CCL5,C4BPA,CCR5,TNFSF4,AQP9,FCGR2B,IL6R,C5AR1,HLA-DQA1,TCF19,MBL2,AZGP1,IL8,CCL25,CCL8,IER3,CCL15,DPP4,IGKC,HAMP,NEDD4,FCGR3B,RGS1,IGHM,C8B,GBP5,AFP,IGJ,CD1D | 0.008114 |
| Leukocyte migration | 11 | ICAM1,IL6,MMP9,PECAM1,VEGFA,ITGA2,THBS1,ADAM10,SELP,ITGB2,SELE | 0.01 |
| Angiogenesis regulation | 9 | Rhob,VASH2,AGGF1,AMOT,ANGPTL3, BTG1,ITGB2, IL1B,HIF1A | 0.01 |
| Cell adhesion | 13 | ADAM9,AGT,CD44,CDK5,COL3A1,COL5A3,CTGF,ECM2,CTNNB1,FN1,ITGA3,ITGA6, RHOA | 0.01 |
| Collagen fibril organization | 8 | COL11A1,COL1A1,COL2A1,COL3A1, COL5A1,SERP1NH1,TGFB2,TGFBR1 | 0.01 |
Figure 4A subgroup of HCC high expressing NTS was confirmed in the expanded pool of 40 microarray data accompanied with significantly up-regulated inflammation-related pathways.
NTS expression in 40 cases of integrated microarray data composing of 9 cases of in-house data and 31 cases of public GEO data. A subgroup of 10 cases of NTS high expressing HCC samples was separated out in the spectral map using the SMA algorithm. A). Quantity of NTS expression at the mRNA level in 40 HCC tissues. NTS was found to be elevated in 10 samples (1–13426, 1–13732, 2–263, 4–3.3, 5–248696, 5–248697, 5–248712, 5–248724, 5–248727, 5–248728). B). These 10 NTS high expressing samples(red box) clustered on the left side of the spectral map, in which NTS was shown as one of the top 20 highly expressed genes. C). LIMMA analysis was performed to identify the differentially expressed genes between NTS high and low expressing samples, and a panel of 457 gene was generated, including 166 up-regulated genes and 291 down-regulated genes. D). The LIMMA analysis was repeated after 10 normal adjacent tissues were integrated to screen NTS related differentially expressed genes. A list of 123 common up-regulated genes in NTS high expressing samples was generated which can distinctively distinguish NTS over-expressing cancer samples (red box) from the others in the heat map (blue box). E).Top 10 pathways dysregulated in NTS high expressing samples were enriched from the 123 common up-regulated genes. The inflammation-related processes and invasion-related signal pathways were up-regulated in NTS over-expressing tissues.
Figure 5All significantly differentially expressed genes between high and low NTS samples were put into Pathway Studio® to screen the candidates that were regulated by or interacted with NTS.
The NTS/IL-8 pathway, a predominant inflammation-related pathway in colorectal carcinogenesis was distinguished. A). Up-regulated NTS expression closely correlated with increase of multiple inflammatory molecules. B). Direct interaction between NTS and chemotaxin IL-8 was confirmed.
Figure 6Synchronous increase of NTS and IL-8 proteins in cancer cells closely correlated with the up-regulated inflammatory response in microenvironment of HCC.
The expression of multiple protein markers in HCC was detected in 64 cases of primary HCC tissues and corresponding normal adjacent tissues using IHC staining method. A). Ectopic expression of NTS (red arrowhead) is observed in 17.19% (11/64) of HCC tissues. B). Synchronous and consistent expression of IL-8 (red arrowhead) was observed in 90.91%(10/11) of NTS+ samples, which is much higher than the rate of 54.69% (35/64) among all HCC samples. C). The PRs of IL-8 significantly positively correlated to the PRs of NTS in cancer cells with a linear regression equations of Y = 28.213+0.456X (Y: PRs of IL-8; X: PRs of NTS) (R = 0.316, P = 0.011). D). The expression of VEGF is significantly higher in NTS+IL-8+ HCC samples compared to the others (P = 0.020). E). The expression of MMP9 is significantly higher in NTS+ and NTS+IL-8+ HCC samples(P = 0.004 and P = 0.0051). F). Increased infiltration of CD68+ TAMs was observed in NTS+IL-8+ HCC samples.
Figure 7Co-expression of NTS and IL-8 associated with enhanced EMT in cancer cells.
The expression of three EMT markers: E-Cadherin, β-Catenin and Vimentin was examined to evaluate the status of EMT in NTS+IL-8+ HCC tissues. A-C). Loss of expression of E-Cadherin on membrane and increased accumulation of β-catenin and Vimentin in cytoplasm was found in NTS+IL-8+ HCC samples. Statistical analysis showed that the expression of E-Cadherin and β-catenin significantly correlated with the level of IL-8 in HCC samples. A). E-Cadherin. B). β-catenin. C). Vimentin. Note: 0: Negative of co-expression of NTS and IL-8 in cancer tissues; 1: Positive of co-expression of NTS and IL-8 in cancer tissues.
The correlation between the co-expression of NTS and IL-8n in 64 cases of HCC tissues and multiple clinical-pathological features of the corresponding patients.
| Clinic-pathological features | Case | Expression of NTS |
| Co-expression of NTS and IL-8 |
| |||
| − | + | − | + | |||||
| Gender | Female | 6 | 6 | 0 | 0.241 | 6 | 0 | 0.268 |
| Male | 58 | 47 | 11 | 48 | 10 | |||
| Age | <54.44 y | 35 | 29 | 6 | 0.992 | 30 | 5 | 0.746 |
| ≥54.44 y | 29 | 24 | 5 | 24 | 5 | |||
| HBV infection | No | 16 | 14 | 2 | 0.566 | 14 | 2 | 0.691 |
| Yes | 48 | 39 | 9 | 40 | 8 | |||
| Alcohol history | No | 33 | 28 | 5 | 0.656 | 28 | 5 | 0.914 |
| Yes | 31 | 25 | 6 | 26 | 5 | |||
| Smoke history | No | 26 | 22 | 4 | 0.752 | 23 | 3 | 0.456 |
| Yes | 38 | 31 | 7 | 31 | 7 | |||
| Clinical stage of disease | I | 8 | 6 | 2 | 0.805 | 6 | 2 | 0.681 |
| II | 45 | 38 | 7 | 39 | 6 | |||
| III | 11 | 9 | 2 | 9 | 2 | |||
| Clinical outcome | Alive | 45 | 40 | 5 |
| 41 | 4 |
|
| Dead | 19 | 13 | 6 | 13 | 6 | |||
Note:
−: low expression of NTS or negative of co-expression of NTS and IL-8 in cancer tissues;
+: high expression of NTS or positive of co-expression of NTS and IL-8 in cancer tissues.
Figure 8Synchronous increase of NTS and IL-8 in HCC correlated with worse prognosis and shorten survival of patients after surgery.
The univariate survival analysis between different clinical and pathological parameters of 64 cases of HCC patients was performed using the Kaplan-Meier method and the log-rank test. A-C). None significant difference of OS was observed between patients with and without history of alcohol consumption(A) or HBV infection(B), and patients at different clinical stages(C). D-J). The relationship between the OS and the expression levels of NTS(D), IL-8(E), MMP-9(H), VEGF(I) and CD68(J) was studied. The univariate survival analysis showed that the expression level of NTS exclusively adversely affected the OS of HCC patients(D), in which the patients bearing NTS+ tumors suffered from shorter OS than those bearing NTS− tumors (P = 0.035). The same result was obtained in the patients bearing NTS+IL-8+ tumors (F) whose OS are 3 folds shorter than the others(P = 0.011). Note: 0: Negative/low expression of certain markers in cancer tissues; 1: Positive expression of certain markers in cancer tissues.